Syros Pharmaceuticals Inc (SYRS)
| Sector • Healthcare Industry • Major Pharmaceutical Preparations |
| Industry • Major Pharmaceutical Preparations |
| Sector • Healthcare |
The Deficit has expanded even more at the Syros Pharmaceuticals Inc in the third quarter of 2022
SYRS recorded third quarter of 2022 operating loss of $-39.454 million
Published 2022-11-16T22:24:25+00:00
Goran Soko / CSIMarket.com Contributer
Weak business caused growth in losses for the third quarter of 2022 financial report, Syros Pharmaceuticals Inc s' net deficit per share grew to $-3.21 from $-0.41 where Revenue fell by -31.701 % to $3.89 million from $5.70 million a year before. In contrast to the Q2 Revenue Tumbled by -38.002 % from $6.28 million and increased deficit from $-0.54 per share.
For the third quarter of 2022 Syros Pharmaceuticals Inc realized net deficit of $-30.253 million, higher than $-26.027 million a year ago.
Syros Pharmaceuticals Inc is expected to report next financial earnings on August 08, 2023.